wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38911022-83E96FA8-1D3D-48EE-BE5D-C08A84941811
Q38911022-83E96FA8-1D3D-48EE-BE5D-C08A84941811
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38911022-83E96FA8-1D3D-48EE-BE5D-C08A84941811
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro
P2860
Q38911022-83E96FA8-1D3D-48EE-BE5D-C08A84941811
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38911022-83E96FA8-1D3D-48EE-BE5D-C08A84941811
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1a3229d50f3d2276151ff807eb16f1a7afd9508d
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.